ReviewJournal of human genetics2021
Artificial intelligence powered statistical genetics in biobanks.
Review in Journal of human genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A priori sample size determination and power analysis in metabolic phenotyping and integrative metabolomics: an application framework based on a systematic review of literature.Metabolomics : Official journal of the Metabolomic Society · 2026Pooled it
- Global Biobank Meta-analysis Initiative: How can global health benefit by its use?Journal of global health · 2023Pooled it
- Dynamic consent framework for low-dose CT scan lung cancer screening: autonomy, privacy, ethical data management.Frontiers in digital health · 2026Article
- Biobanking, digital health and privacy: the choices of 1410 volunteers and neurological patients regarding limitations on use of data and biological samples, return of results and sharing.BMC medical ethics · 2024Article
- Review
- Advancements in Umbilical Cord Biobanking: A Comprehensive Review of Current Trends and Future Prospects.Stem cells and cloning : advances and applications · 2024Review
- Unlocking the potential of big data and AI in medicine: insights from biobanking.Frontiers in medicine · 2024Article
- Revolutionizing Cancer Research: The Impact of Artificial Intelligence in Digital Biobanking.Journal of personalized medicine · 2023Review
- A leap of faith: building the trust in human biobanks.Frontiers in genetics · 2023Article
- FAIR principles for AI models with a practical application for accelerated high energy diffraction microscopy.Scientific data · 2022Article
- Identification and Assessment of Risks in Biobanking: The Case of the Cancer Institute of Bari.Cancers · 2022Article
- A Survey on the Role of Artificial Intelligence in Biobanking Studies: A Systematic Review.Diagnostics (Basel, Switzerland) · 2022Review
- Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review.International journal of molecular sciences · 2022Review
- Standard operating procedures for biobank in oncology.Frontiers in molecular biosciences · 2022Article
- Phytochemicals: Do They Belong on our Plate for Sustaining Healthspan?Food frontiers · 2021Article
- An Improved Stacked Autoencoder for Metabolomic Data Classification.Computational intelligence and neuroscience · 2021Article
- Biobanking in the digital pathology era.Oncology research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large-scale, sometimes nationwide, prospective genomic cohorts biobanking rich biological specimens such as blood, urine and tissues, have been established and released their vast amount of data in several countries. These genetic and epidemiological resources are expected to allow investigators to disentangle genetic and environmental components conferring common complex diseases. There are, however, two major challenges to statistical genetics for this goal: small sample size-high dimensionality and multilayered-heterogenous endophenotypes. Rather counterintuitively, biobank data generally have small sample size relative to their data dimensionality consisting of genomic variation, lifestyle questionnaire, and sometimes their interaction. This is a widely acknowledged difficulty in data analysis, so-called "p»n problem" in statistics or "curse of dimensionality" in machine-learning field. On the other hand, we have too many measurements of individual health status, which are endophenotypes, such as health check-up data, images, psychological test scores in addition to metabolomics and proteomics data. These endophenotypes are rich but not so tractable because of their worsen dimensionality, and substantial correlation, sometimes confusing causation among them. We have tried to overcome the problems inherent to biobank data, using statistical machine-learning and deep-learning technologies.
Indexed as
Identifiers
32782383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.